Pharmaceutical Industry discussion, review, analysis, news and information.

Phase IIa trials conducted by Transition Therapeutics Inc. (TSE: TTH) for its regenerative product, E1-I.N.T.™, demonstrated safety, efficacy and tolerability in type 1 and type 2 diabetes patients.

Data from the trial in type 2 diabetes patients demonstrated that E1-I.N.T.™ significantly lowered blood glucose levels for patients using metformin with/without thiazolidinediones (TZD).

In the type 1 diabetes study, 6 of 11 (54%) patients responded to E1-I.N.T.™ therapy, either by decreasing their average daily insulin usage by more than 20% or reducing their HbA1c levels by 1.2 to 2%.

E1-I.N.T.™ is the first of a series of gastrin-based diabetes therapies developed by Transition (from its I.N.T.™ technology platform) to be clinically evaluated in type 1 and type 2 diabetes patients.

Find more details of the clinical data from the press release.